Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) released its earnings results on Friday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Helix Biopharma stock remained flat at $1.71 during trading hours on Friday. The firm has a market cap of $130.61 million, a PE ratio of -34.20 and a beta of 0.17. The firm has a fifty day simple moving average of $1.72 and a 200 day simple moving average of $1.73. Helix Biopharma has a 12-month low of $1.71 and a 12-month high of $1.73.
About Helix Biopharma
Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.
Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe.
Read More
- Five stocks we like better than Helix Biopharma
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
